OOIR: Observatory of International Research

Papers

(The TQCC of Biomarker Research is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Mitochondrial transfer in hematological malignancies	156
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	154
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	146
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	133
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	125
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	124
Advances in the DNA methylation hydroxylase TET1	114
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	108
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	103
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	92
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	85
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	77
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	77
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	75
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	73
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	71
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	69
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	66
p53 biology and reactivation for improved therapy in MDS and AML	65
Donor T cells for CAR T cell therapy	64
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	63
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	62
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	61
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	61
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	59

Unveiling the potential of CLL-1: a promising target for AML therapy	59
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	58
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	58
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	58
Targeting interleukin-1β and inflammation in lung cancer	56
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	55
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	54
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	54
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	53
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	53
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	52
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	52
The role and metabolic adaptations of neutrophils in premetastatic niches	51
The role of BATF in immune cell differentiation and autoimmune diseases	51
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	51
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	51
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	50
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	49
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	47
Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas	46
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma	44
Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions	44
Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia/lymphoma	44
Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities	42
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	41
BRD4: an effective target for organ fibrosis	41
Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis	40
Correction: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	40
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	39
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	39
Nucleases as molecular targets for cancer diagnosis	39
Comparison of proton therapy and photon therapy for early-stage non-small cell lung cancer: a meta-analysis	37
Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected	37
The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study	37
Intratumor microbiome in cancer progression: current developments, challenges and future trends	37
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	37
Updates on CAR T cell therapy in multiple myeloma	35
Correction: Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	35
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	34
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	34
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	34
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer	32
The importance of critically short telomere in myelodysplastic syndrome	32
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors	32
Analyzing PKC Gamma (+ 19,506 A/G) polymorphism as a promising genetic marker for HCV-induced hepatocellular carcinoma	32
Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia	32
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	31
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer	31
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer	30
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer	30

High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort	29
Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes	29
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients	29
Single-cell RNA sequencing identifies a subtype of FN1 + tumor-associated macrophages associated with glioma recurrence and as a biomarker for immunotherapy	29
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	28
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	28
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	28
Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application	27
Tobacco smoking associates with NF1 mutations exacerbating survival outcomes in gliomas	27
Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy	27
Adipose-derived stem cell exosomes: mechanisms and therapeutic potentials in wound healing	27
Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma	26
NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer	26
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples	26
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives	26
Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer	25
A plasma 9-microRNA signature for lung cancer early detection: a multicenter analysis	25
RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation	25
FGL1 and FGL2: emerging regulators of liver health and disease	24
Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer	24
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	23
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics	23
New cell sources for CAR-based immunotherapy	22
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States	22
Extracellular matrix: unlocking new avenues in cancer treatment	22
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	22
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma	22
S100A9 as a potential novel target for experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome	21
T cells in cancer: mechanistic insights and therapeutic advances	21
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia	21
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool	21
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs	21
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification	21
Association between circulating ECM-associated molecules and cardiovascular outcomes in hemodialysis patients: a multicenter prospective cohort study	21
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer	20
Single-cell multi-omics analysis identifies SPP1+ macrophages as key drivers of ferroptosis-mediated fibrosis in ligamentum flavum hypertrophy	20
Application of double-negative T cells in haematological malignancies: recent progress and future directions	20
Correction: CRISPR/Cas-based CAR-T cells: production and application	20
Human induced-T-to-natural killer cells have potent anti-tumour activities	20
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	20
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology	20
USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition	20
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer	19
SRTdb: an omnibus for human tissue and cancer-specific RNA transcripts	19
Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia	19
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases	19
MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage	19
Toll-like receptor 3: a double-edged sword	18
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma	18
A germline FLT3 variant in aplastic anemia	18
Targeting TIGIT for cancer immunotherapy: recent advances and future directions	18
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies	18
The significant others of aurora kinase a in cancer: combination is the key	18
The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer	18
PCSK9 in T-cell function and the immune response	18
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals	18